Article

Mylan Issues Statement in Response to Abbott's Support for Perrigo Transaction

Mylan N.V. today issued a statement regarding Abbott Laboratories' announced intention to support Mylan's offer to acquire Perrigo Company plc.

PRESS RELEASE

HERTFORDSHIRE, England

and

PITTSBURGH

,

June 16, 2015

/PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today issued the following statement regarding Abbott Laboratories' (NYSE: ABT) announced intention to support Mylan's offer to acquire Perrigo Company plc (NYSE: PRGO; TASE) and vote in favor of this acquisition at Mylan's upcoming shareholder meeting.

Abbott

is currently Mylan's largest shareholder, owning 14.5% of Mylan's outstanding shares, and is an important long-term stakeholder of Mylan through various manufacturing partnerships.

Mylan Executive Chairman

Robert J. Coury

stated: "We are very pleased that, while

Abbott

is under no obligation to do so,

Abbott

has voluntarily chosen to express its support of Mylan, our strategic growth plan and stand-alone strategy, and our proposed combination with Perrigo. When we acquired

Abbott's

non-U.S. developed markets specialty and branded generics business earlier this year, we gained an important stakeholder in

Abbott

, which understands the powerful potential of our platform, and the critical importance of our scale and breadth across our distribution channels. We are grateful for

Abbott's

support of our long-term vision, which we firmly believe will continue to deliver strong near-term and long-term returns in this rapidly evolving industry and will promote the sustainable success of Mylan's business."

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com